Navana Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 1/6
Navana Pharmaceuticals has a total shareholder equity of BDT4.5B and total debt of BDT4.8B, which brings its debt-to-equity ratio to 105.9%. Its total assets and total liabilities are BDT10.4B and BDT5.9B respectively. Navana Pharmaceuticals's EBIT is BDT865.7M making its interest coverage ratio 3. It has cash and short-term investments of BDT328.9M.
Key information
105.9%
Debt to equity ratio
৳4.79b
Debt
Interest coverage ratio | 3x |
Cash | ৳328.92m |
Equity | ৳4.52b |
Total liabilities | ৳5.85b |
Total assets | ৳10.38b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: NAVANAPHAR's short term assets (BDT5.2B) do not cover its short term liabilities (BDT5.4B).
Long Term Liabilities: NAVANAPHAR's short term assets (BDT5.2B) exceed its long term liabilities (BDT410.9M).
Debt to Equity History and Analysis
Debt Level: NAVANAPHAR's net debt to equity ratio (98.6%) is considered high.
Reducing Debt: Insufficient data to determine if NAVANAPHAR's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: NAVANAPHAR's debt is not well covered by operating cash flow (1.9%).
Interest Coverage: NAVANAPHAR's interest payments on its debt are not well covered by EBIT (3x coverage).